Enrollment Complete In Pivotal Phase 3 Trial Of Medidur(TM) FA For Diabetic Macular Edema

Alimera Sciences Inc., a privately held ophthalmic pharmaceutical company, and pSivida Limited (Nasdaq: PSDV; ASX: PSD; Xetra: PSI), announced that enrollment is complete for the FAME(TM) (Fluocinolone Acetonide in Diabetic Macular Edema) Study of Medidur(TM) FA for the treatment of Diabetic Macular Edema. FAME is a double masked, randomized, multi-center study that is following over 900 patients in the U.S. [click link for full article]

More: continued here

Filed under: Diabetes on October 9th, 2007